

Company Update

RM Group Holdings Limited 8185 HK

Get ready for a fruitful 2014!

- RM Group's 1Q-3Q results for FY03/14 was negatively affected by one-off expenses including share-based payments and listing expenses, which cumulatively amounted to HKD22.7m during the 9-month period
- SG&A to sales ratio increased by 11.0ppt to 61.8% in 1Q-3Q FY03/14. However, we expect it will normalize in FY03/15, and the increase in marketing expenses will translate to higher revenue growth in the future
- □ We expect the company will see substantial growth in turnover and profit in 1Q FY03/15, due to the absence of listing expenses and new product launch

RM Group is principally engaged in the business of formulating, marketing, sales and distribution of health and beauty supplements in Hong Kong and Taiwan.

What's New: RM Group announced the quarterly results for 3Q FY03/14. During the 3-month period, the company's revenue was up by 27.6% YoY to HKD56.2m, mainly driven by the increase in the sales of health supplement and beauty supplement products, which were up by 31.8% YoY and 7.7% YoY respectively. Gross margin was 78.9%, which similar to the historical level. However, the company recorded an operating loss for the period due to higher SG&A expenses (3Q FY03/14: HKD32.4m vs. 3Q FY03/13:20.6m), higher share-based payments (HKD7.4m), and listing expenses (HKD11.1m). The company recorded a net loss attributable to shareholders of HKD9.6m in 3Q FY03/14, as compared to a net profit attributable to shareholders of HKD9.9m in the same period last year.

For 1Q-3Q FY03/14, the company's revenue was up by 10.7% YoY to HKD130.4m. The company recorded a net loss attributable to shareholders of HKD5.4m as compared to a net profit attributable to shareholders of HKD22.9m in the same period last year.

In fact, the company has announced a profit warning in late January, stating that the company is expected to record a loss for Q1-Q3 FY03/14. The loss was mainly due to an increase in listing expenses and share-based payments for share options granted. The loss, therefore, was within market expectation and should not be a surprise to the market.

Figure 1: Forecasts and Valuation FY03/12 FY03/13 FY03/14E FY03/15E FY03/16E HKD '000 HKD '000 HKD '000 HKD '000 HKD '000 Revenue 158,793 163,767 175,259 189,680 207,663 Gross profit 126,344 129,010 128,710 148,861 163,118 61,666 Profit from operation 52.725 46 594 11.712 55.520 Net profit attributable to shareholders 43,032 39.264 9,172 45,309 49.047 Net profit attributable to shareholders (adjusted for listing 45,422 40,652 27,124 45,309 49,047 expenses and share-baesd payment) 1.8 8.8 9.5 EPS - Basic (HK cents) EPS - Diluted (HK cents) 1.7 8.2 8.9 P/E (x) 99.4 20.1 18.6 P/B (x) 5.6 4.9 4.4

Source: The company, SBI E2-Capital


(852) 2533 3708 sbie2research@sbie2capital.com

Stock Data (8185 HK)

Rating	Not Rated
Price (HK\$)	1.74
Target Price (HK\$)	n.a.
12m Price Range (HK\$)	1.07-2.95
Market cap. (HK\$m)	896.1
Daily t/o (HK\$m)	1.6
Free float (%)	25.2
Source: Bloomberg	-



FY03/14 profit negatively affected by one-off expenses: The company recorded share-based payments and listing expenses of HKD7.4m and HKD15.4m for the 1Q-3Q FY03/14. In fact, stripping off those one-off expenses the company would have recorded profit before tax of HKD21.3m during the 9-month period, as compared to HKD29.8m in the corresponding period last year. Similarly to other newly listed companies in HK, the company's P/L was negatively affected by the related listing expenses after its IPO. However, as those expenses were mostly one-off in nature, we believe the company will have a good chance to turn around next year.



Source: The company

Health supplements continue to lead growth: Health supplements, in which Royal Medic CS-4 is categorized, were up by 20.7% YoY to HKD99.4m in 1Q-3Q FY03/14, accounting for 76.2% of the company's total revenue during the period. We expect that health supplements will continue to lead growth as our financial model forecasts that this segment will grow by 8.4%, 9.4% and 11.0% in FY03/14, FY03/15, and FY03/16 respectively.

Revenue breakdown	1Q-3Q FY03/14 HKD'000	1Q-3Q FY03/13 HKD'000	YoY Change
lealth Supplements			
Proprietary brands	80,125	71,790	12%
Private label brands	19,291	10,603	82%
	99,416	82,393	21%
Beauty supplements			
Proprietary brands	22,783	21,287	7%
Private label brands	7,583	13,570	-44%
	30,366	34,857	-13%
Others	639	558	15%
Fotal	130,421	117,808	11%


Source: The company

Increases in marketing expenses will translate into higher turnover in the future: The Company's SG&A to sales ratio increased by 11.0ppt to 61.8% in 1Q-3Q FY03/14 from 50.8% in 1Q-3Q FY03/14. The increase in SG&A was mainly due to increases in marketing expenses, which were up by HKD4.8m in 3Q FY03/14. Although it is true that the increase in marketing expenses will drag down profit during the period, we believe it will be a good investment and will have an overall positive effect on its future business, because i) turnover in 1Q-3Q FY03/14 was up by 10.7% YoY to HKD130.4m, being the testament of the effective marketing expenses; ii) the company will launch a number new health-care products, including 4 new products together developed with the CUCAMed, in FY03/15; and iii) its Taiwan business is in its n initial stages (accounted for 1.1% of total revenue in 1Q-3Q FY03/14), and marketing expenses are expected to translate into higher turnover and thereby higher business growth in the future.

We also believe that the SG&A to sales ratio will normalize in FY03/15, due to cost containment measures implemented by the company, and the reduction of IPO related marketing expenses next year.



Figure 4: SG&A to sales ratio



Source: the company

We expect the company will see strong growth in turnover and profit in 1Q FY03/15. Based on the assumptions that health supplements will lead growth and will increase by 8.4% YoY, 9.4% YoY, and 11.0% YoY in FY03/14, FY03/15 and FY03/16, we expect the corresponding revenue of the company will increase by 7.0% YoY, 8.2% YoY, and 9.5% YoY to HKD175.3m, 189.7HKD m and HKD207.7m. We also forecast the corresponding net profit attributable to shareholders will be HKD9.2m, HKD45.3m, and HKD49.0m, respectively.

We expect the company will see a strong growth in its turnover and profit in 1Q FY03/15, because i) there will be no listing expenses in FY03/15, and ii) there will be a number of new products being launched in 1Q FY03/15, including 4 new products together developed with the CUCAMed. We believe the new products will gain popularity in the market and will contribute to the turnover and profit of the company.

Valuation. The international peers of the company, including Herbalife (HLF US), Nu Skin (NUS US), USANA (USNA US), FANCL (4921 JP), and Eu Yan Sang (EYSAN SP), are on average trading at a trailing 12-month historical P/E of 16.0x and a prospectively P/E of 32.1x for 2013.

Figure 5. Peer Comparison	(International)							
Name	Ticker	Market Cap (HK\$ m)	Trailing 12M EV/EBITDA	Price to EBITDA	2012 P/E (x)	2013E P/E (x)	P/book (x)	ROE (%)
FANCL	4921 JP	5,944.59	n.a.	12.25	n.a.	104.16	1.09	-4.96
Eu Yan Sang International	EYSAN SP	2,218.41	13.86	10.36	20.25	18.84	2.52	13.09
Herbalife Ltd.	HLF US	52,007.68	8.96	8.68	12.91	12.36	14.76	126.20
Nu Skin Enterprises	NUS US	35,252.61	10.40	8.92	15.63	12.86	6.02	46.23
USANA Health Science	USNA US	8,132.30	8.75	8.36	13.57	12.52	4.02	35.43
	Average	20,711	10.49	9.71	15.59	32.15	5.68	43.20

Source: Bloomberg, SBI E2-Capital

As for HK-listed peers, there are six companies that are engaged in manufacturing and selling of healthcare products in HK and China. These companies include Wai Yuen Tong (897 HK), Tong Ren Tang (1666 HK), Beijing Tong Ren Tang Chines (8138 HK), CK Life Sciences International (775 HK), Besenyen (926 HK) and Reak Nutriceutical (2010 HK). On average, these companies are trading at a trailing 12-month P/E of 19.85x and a prospective P/E of 36.0x for 20113.

Figure 6. Peer Comparison (HK)

Name	Ticker	Mkt Cap (HK\$ m)	Trailing 12M EV/EBITDA	Price to EBITDA	2012E P/E (x)	2013E P/E (x)	P/book (x)	ROE (%)
Wai Yuen Tong Medicine	897 HK	618.47	10.98	9.31	2.99	n.a.	0.36	11.04
Tong Ren Tang Technologies	1666 HK	17,674.82	16.51	20.13	33.20	29.93	5.81	19.17
CK Life Sciences International	775 HK	7,977.19	18.03	15.25	39.71	n.a.	1.60	3.89
Besunyen Holdings	926 HK	604.23	n.a.	n.a.	n.a.	n.a.	0.38	-13.55
Beijing Tong Ren Tang Chines	8138 HK	9,229.60	n.a.	n.a.	n.a.	41.96	n.a.	n.a.
Reak Nutriceutical	2010 HK	2,043.93	1.53	2.11	3.51	n.a.	0.45	13.60
	Average	6,358	11.76	11.70	19.85	35.95	1.72	6.83

Source: Bloomberg, SBI E2-Capital



Figure 7: Income Statement

	FY03/12	FY03/13	FY03/14E	FY03/15E	FY03/16E
	HKD '000				
Revenue	158,793	163,767	175,259	189,680	207,663
Cost of good sold	(32,449)	(34,757)	-46,549	-40,819	-44,545
Gross profit	126,344	129,010	128,710	148,861	163,118
other revenue and other net income	31	1337	2,629	1,477	2,380
Selling, distribution and administrative expenses	-70,729	-82,110	-96,893	-94,818	-103,831
Listing expenses & share based payment	-2,921	-1,643	-22,734	0	0
Profit from operations	52,725	46,594	11,712	55,520	61,666
Finance costs	-131	-110	-97	-97	-97
Profit before taxation	52,594	46,484	11,615	55,423	61,570
Taxation	-9,562	-7,220	-2,443	-10,114	-12,522
Profit attributable to shareholders	43,032	39,264	9,172	45,309	49,047
EPS - Basic (HK cents)			1.8	8.8	9.5
- Diluted (HK cents)			1.7	8.2	8.9

Source: The Company

Figure 8: Ratio Analysis

	FY03/12	FY03/13	FY03/14E	FY03/15E	FY03/16
Growth (YoY)					
Revenue	-	3.1%	7.0%	8.2%	9.5%
Gross profit	-	2.1%	-0.2%	15.7%	9.6%
Operating profit	-	-11.6%	-74.9%	374.1%	11.1%
Net profit	-	-8.8%	-76.6%	394.0%	8.3%
Margin					
Gross margin	79.6%	78.8%	73.4%	78.5%	78.5%
Operating margin	33.2%	28.5%	6.7%	29.3%	29.7%
Net profit margin	27.1%	24.0%	5.2%	23.9%	23.6%
Other Ratios					
Return on asset	48.1%	47.3%	4.7%	18.6%	17.5%
Return on equity	109.5%	101.8%	5.7%	24.5%	23.4%
Valuation					
P/E (x)	-	-	99.4	20.1	18.6
P/B (x)	-	-	5.6	4.9	4.4

Source: The Company

Figure 9: Segment Financials

FY03/13 HKD '000	FY03/14E HKD '000	FY03/15E HKD '000	FY03/16E HKD '000
105168	114,244	125,154	139,052
14914	15,958	17,235	18,958
27203	28,250	29,832	31,516
15637	15,921	16,528	17,159
845	887	932	978
0%	9%	10%	11%
292%	7%	8%	10%
-10%	4%	6%	6%
			4%
	-10% -16% 56%	-16% 2%	-16% 2% 4%

Source: The Company



Figure 10: Balance Sheet

	HKD '000	HKD '000	FY03/14 HKD '000	FY03/15 HKD '000	FY03/16 HKD '000
Non-current assets	40.000			40.000	15 001
Property, plant and equipment Integible asset	16,303 0	16,868 0	16,944 800	16,628 800	15,921 800
integible asser	16,303	16,868	17,744	17,428	16,721
Current assets					
Inventories	11.109	12,765	15.164	9,327	17,401
Trade and other receivables	27,304	32,572	25,047	37,313	30,960
Pledged bank deposit	0	5,000	0	0	0
Cash and cash equivalents	34,812	15,708	135,755	179,312	214,455
Tax recoverable	0	16	655	655	655
	73,225	66,061	176,622	226,607	263,470
Current liabilities					
Trade and other payables	21,694	13,202	23,405	32,351	42,114
Obligations under finance lease	90	47	0	0	0
Secured bank loans	4,020	3,491	3,221	3,221	3,221
Amounts due to related parties	2,418	26,529	0	0	0
Dividend Payable	0	0	4,586	22,654	24,524
Tax payables	21,076	0	0	0	0
Provisions	860	1,038	946	946	946
	50,158	44,307	32,157	59,172	70,805
Non-current liabilities					
Obligations under finance lease	47	0	0	0	0
Deferred tax liabilities	36	71	71	71	71
	83	71	71	71	71
Net Asset	39,287	38,551	162,137	184,791	209,315
EQUITY					
Equity attributable to owners of the Company					
Share capital	0	0	10	10	10
Reserves	39,287	38,551	162,127	184,781	209,305
TOTAL EQUITY	39,287	38,551	162,137	184,791	209,315

Source: The Company

Figure 11: Cash Flow Statement

	FY03/12	FY03/13	FY03/14	FY03/15	FY03/16
	HKD'000	HKD'000	HKD'000	HKD'000	HKD'000
OPERATING ACTIVITIES					
Profit before taxation	52,594	46,484	11,615	55,423	61,570
Adjustments for:	0	0	0	0	0
Finance costs	131	110	97	97	97
Write down of inventories	1,962	1,147		0	0
Reversal of write-down of inventories	-453	-508	-92	0	0
Depreciation on property, plant and equipment	884	1,467	1,924	2,316	2,707
Bank interest income	-12		0	0	0
Net gain on disposal of property, plant and equipment	0	-1,246	0	0	0
	55,106	47,454	13,544	57,835	64,373
Changes in working capital					
Increase in inventories	-6,969	-2,295	-2,399	5,838	-8,074
Increase in trade and other receivables	-6,439	-5,268	7,525	-12,266	6,353
Decrease in amount due from a related party	278	0	0	0	0
Increase/(decrease) in trade and other payables	8,353	-8,492	10,203	8,947	9,763
Decrease in amounts due to related parties	-2,596	-2,389	0	0	0
(Decrease)/increase in provisions	-112	178	0	0	0
CASH GENERATED FROM OPERATIONS	47,621	29,188	28,872	60,354	72,416
Hong Kong profits tax paid	-133	-28,277	-3,082	-10,114	-12,522
NET CASH GENERATED FROM OPERATING ACTIVITIES	47,488	911	25,789	50,240	59,893
INVESTING ACTIVITIES					
Purchase of property, plant and equipment	-5,991	-2,886	-2,000	-2,000	-2,000
Proceeds from sale of property, plant and equipment	0	2,100	0	0	0
Increase in intengible assets	0	0	-800		
Bank interest received	12	0	0	0	0
Increase in pledged bank deposit	0	-5,000	5,000	0	0
NET CASH USED IN INVESTING ACTIVITIES	-5,979	-5,786	2,200	-2,000	-2,000
FINANCING ACTIVITIES				_	
Proceeds from IPO	545	500	119,000	0	0
Repayment of secured bank loans	-515	-529	-270	0	0
Interests paid	-119 -29.921	-104 -13.500	-97 -26.529	-97 0	-97 0
Decrease in amounts due to related parties	-29,921 -84	-13,500 -90	-26,529 -47	0	0
Capital element of finance lease payments	-84 -12	-90 -6	-47	0	0
Interest element of finance lease payments Dividend paid	-12	-6	0	-4.586	-22.654
NET CASH USED IN FINANCING ACTIVITIES	-30,651	-14,229	92,057	-4,682	-22,054 -22,751
Net increase/ decrease in cash and cash equivalent	10,858	-19,104	120.047	43,557	35,143
cash and cash equivalent athe the end of last period	23,954	34,812	15,708	135,755	179,312
Exchange rate effect	0	0	0	0	0
cash and cash equivalent at the end of the current period	34,812	15,708	135,755	179,312	214,455

Source: The Company



SBI E2-Capital is a dedicated small/mid cap investment banking/ stockbrokerage house. Find our research on: sbie2capital.com, thomsononeanalytics.com, factset.com and multex.com

SBI E2-Capital stock ratings:

STRONG BUY	: absolute upside of >50% over the next three months
BUY	: absolute upside of >10% over the next six months
HOLD	: absolute return of -10% to +10% over the next six months

SELL : absolute downside of >10% over the next six months

Investors should assume that SBI E2-Capital is seeking or will seek investment banking or other related businesses with the companies in this report.

Analyst certification: The views expressed in this report accurately reflect the analyst's personal views of the subject securities and that the analyst has not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report.

Disclosure of interest: SBI E2-Capital was the IPO underwriter of the company in September 2013.

Disclaimer:

This research report is not an offer to sell or the solicitation of an offer to buy or subscribe for any securities. The securities referred to in this report may not be eligible for sale in some jurisdictions. The information contained in this report has been compiled by the Research Department of SBI E2-Capital Financial Services Limited ('SBI E2-Capital') from sources that it believes to be reliable but no representation, warranty or guarantee is made or given by SBI E2-Capital or any other person as to its accuracy or completeness. All opinions and estimates expressed in this report are (unless otherwise indicated) entirely those of SBI E2-Capital as of the date of this report only and are subject to change without notice. Neither SBI E2-Capital nor any other person, accepts any liability whatsoever for any loss howsoever arising from any use of this report or its contents or otherwise arising in connection therewith. Each recipient of this report shall be solely responsible for making its own independent investigation of the business, financial condition and prospects of the companies referred to in this report. SBI E2-Capital and their respective officers, directors and employees, including persons involved in the preparation or issuance of this report, may from time to time (1) have positions in, and buy or sell, the securities of companies referred to in this report (or related investments); (2) have a consulting, investment banking or broking relationship with any company referred to in this report; and (3) to the extent permitted under applicable law, have acted upon or used the information contained or referred to in this report including effecting transactions for their own account in an investment (or related investment) in respect of any company referred to in this report, prior to or immediately following its publication. This report may not have been distributed to all recipients at the same time. This report is issued only for the information of and may only be distributed to professional investors and dealers in securities and must not be copied, published, reproduced or redistributed (in whole or in part) by any recipient for any purpose. This report is distributed in Hong Kong by SBI E2-Capital. Any recipient of this report who requires further information regarding any securities referred to in this report should contact the relevant office of SBI E2-Capital located in such recipient's home jurisdiction.

Copyright© SBI E2-Capital Financial Services Limited. All rights reserved.